Principal Securities’s Humacyte HUMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-15
Closed -$31 3786
2025
Q2
$31 Sell
15
-235
-94% -$451 ﹤0.01% 3666
2025
Q1
$1.26K Hold
250
﹤0.01% 3156
2024
Q4
$1.26K Sell
250
-250
-50% -$1.24K ﹤0.01% 3150
2024
Q3
$2.72K Sell
500
-500
-50% -$3.3K ﹤0.01% 2860
2024
Q2
$4.8K Buy
+1,000
New +$5.21K ﹤0.01% 2654

Other funds holding HUMA

Principal Securities's HUMA Position: Q3 2025 in Review

Principal Securities sold out of Humacyte (HUMA) in Q3 2025, closing a stake of 15 shares — an estimated $31 sold.

Principal Securities first reported a position in HUMA in Q2 2024 and held it in 5 quarters. The position peaked at $4.8K in Q2 2024. 141 funds tracked by Wall St. Rank hold HUMA as of Q3 2025.

  • Principal Securities reported no remaining Humacyte position as of Q3 2025 after selling out during the quarter.
  • Principal Securities sold 15 Humacyte shares in Q3 2025, an estimated $31.
  • Principal Securities first reported a position in Humacyte in Q2 2024 and held it in 5 quarters.
  • Principal Securities's Humacyte position peaked at $4.8K in Q2 2024.
  • 141 funds tracked by Wall St. Rank held Humacyte as of Q3 2025.

Based on Principal Securities's 13F filing for Q3 2025, filed 12 Nov 2025.